FDA Inspection
Tulex Pharmaceuticals Inc.Tulex Pharmaceuticals Inc. – FDA Inspection, Mar 24, 2025
Record Details
This FDA Inspection record concerns Tulex Pharmaceuticals Inc., with an inspection on March 24, 2025, issued by the New Jersey District Office, covering human drugs.
View Company Profile
ID · 3085aa66-b7a0-4815-9e58-5d1875897b55
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1264812
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
2- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.192Investigations of discrepancies, failures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Tulex Pharmaceuticals Inc.
5| Date | Classification | Office | Project area |
|---|---|---|---|
| December 5, 2024 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| February 29, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| August 14, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 5, 2018 | Not classified | New Jersey District Office | |
| November 21, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Tulex Pharmaceuticals Inc.
- FDA Inspection 1256966 - 2024-12-05
- FDA Inspection 1232755 - 2024-02-29
- FDA Inspection 1129002 - 2020-08-14
- FDA Inspection 1053140 - 2018-04-05
- FDA Inspection 1031819 - 2017-11-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.